Quince Therapeutics, INC

Quince Therapeutics announces conditional resignations of CEO Dirk Thye and COO Brendan Hannah, with Brigette Roberts and John Militello conditionally appointed to lead.

Quince Therapeutics has completed the acquisition of Orphai Therapeutics, integrating Orphai's lead asset LAM-001, an inhaled rapamycin formulation, into its pipeline for treating serious pulmonary disorders.

Quince Therapeutics has finalized a 1-for-20 reverse stock split effective June 29, 2026, to consolidate its common shares.

Quince Therapeutics will implement a 1-for-20 reverse stock split effective June 29, 2026, to consolidate its outstanding common shares.

Quince Therapeutics shareholders approved a reverse stock split and the election of a director at the 2026 Annual Meeting.

Quince Therapeutics has successfully regained compliance with Nasdaq's minimum stockholders' equity listing requirement.

Quince Therapeutics reported disappointing Phase 3 trial results for eDSP, leading to the discontinuation of its development and a pivot towards exploring strategic alternatives, including a potential reverse merger.

Quince Therapeutics reported increased net losses and R&D expenses for Q3 2025, raising substantial doubt about its ability to continue as a going concern despite clinical trial progress and recent financing.

Quince Therapeutics reports progress in its Phase 3 A-T trial and secures a strategic partnership, but faces substantial doubt about its ability to continue as a going concern.

Quince Therapeutics reports a net loss of $15.03 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to insufficient funding.

Quince Therapeutics' Q3 2024 report highlights progress in the EryDex Phase 3 trial, alongside financial updates and a waiver of a key debt covenant.

Quince Therapeutics reported its second quarter 2024 results, including a significant goodwill impairment charge, while also highlighting progress in its Phase 3 clinical trial for EryDex.

Quince Therapeutics announced the discontinuation of its eDSP program for A-T due to unsuccessful Phase 3 trial results and is now exploring strategic alternatives, including a reverse merger.

Quince Therapeutics details its 2024 activities, highlighting the Phase 3 NEAT trial for eDSP in A-T and strategic focus on rare disease treatments.

Quince Therapeutics, Inc. released its 10-K filing for fiscal year 2023, highlighting its strategic shift towards rare disease therapeutics and the advancement of its lead asset, EryDex.

Quince Therapeutics director David Lamond was granted 2,700 stock options as part of a standard equity compensation package.

Director Christopher J. Senner was granted 2,700 stock options in Quince Therapeutics, Inc. as part of a standard equity compensation arrangement.

Chief Corporate Affairs Officer Brigette Roberts reports the exchange of Orphai Therapeutics stock options for Quince Therapeutics options following a merger.

Quince Therapeutics' CEO and CMO, Dirk Thye, was granted 1,000,000 employee stock options with an exercise price of $3.08, vesting monthly through December 2029.

Quince Therapeutics President Charles S. Ryan acquired 200,000 employee stock options with an exercise price of $3.08, vesting through December 2029.

Brendan Hannah, Quince Therapeutics' CBO, COO, and CCO, was granted 365,000 employee stock options with an exercise price of $3.08.

Quince Therapeutics announces its 2026 Annual Meeting, seeking shareholder approval for a reverse stock split to maintain Nasdaq compliance.

Quince Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Quince Therapeutics is asking stockholders to approve an amendment to increase authorized shares and effect a reverse stock split at the upcoming annual meeting.

Quince Therapeutics, Inc. will hold its 2024 Annual Meeting virtually on June 5, 2024, and is asking stockholders to vote on key proposals, including a reverse stock split.

Quince Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024, including proposals for director elections, a reverse stock split, auditor ratification, and executive compensation approval.

Millennium Management LLC and affiliated entities have reported a significant beneficial ownership stake of 7.2% in Quince Therapeutics, Inc.

Nantahala Capital Management, LLC and its principals have reported a 7.52% beneficial ownership stake in Quince Therapeutics, Inc. as of March 31, 2026.

Group One Trading LLC has reported a passive 10.67% beneficial ownership stake in Quince Therapeutics, Inc., primarily through common stock and options.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Quince Therapeutics, Inc., including exercisable warrants.

Genextra S.p.A., Francesco Micheli, and Matteo Bruno Renzulli have reported 0% beneficial ownership in Quince Therapeutics, Inc., indicating a full divestment of their previously held stake.

Nantahala Capital Management, LLC and its managing members disclosed a 9.99% beneficial ownership stake in Quince Therapeutics, Inc. common stock.